Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

Abstract: The present invention relates to recombinant Gram-negative bacterial strains and the use thereof for delivery of repeated domains of a heterologous protein or two or more domains of different heterologous proteins into eukaryotic cells.

Abstract: The invention relates to a method for classifying a tissue sample obtained from mammary carcinoma. The method comprises determining a stiffness value for each of a plurality of points on said tissue sample, resulting in a stiffness distribution, and assigning said sample to a breast cancer subtype and nodal status based on said stiffness distribution.

Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, composed of the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each composed of an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

Abstract: A medical endodevice for an intervention inside a human or animal body includes an elongated liaising structure having a distal end arrangeable inside a body of the human or animal being and a proximal end arrangeable outside the body while the distal end is inside the body. The endodevice has an intervention tool arranged to manipulate a target tissue inside the human or animal body. The intervention tool is arranged at the distal end of the liaising structure. The endodevice further includes a positioning unit having a moving formation arranged to dislocate the intervention tool relative to the target tissue, and an anchoring formation arranged to fix the moving formation to a fixing tissue inside the human or animal body such that the target tissue is positioned in a workspace of the intervention tool.

Abstract: The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.

Abstract: The invention relates to a method to determine a homology directed repair (HDR) event within a eukaryotic cell, wherein the cell expresses a first isoform of a surface protein, which is different from a second isoform of said surface protein with regard to an amino acid marker. The method comprises the steps of inducing a DNA double strand break, providing a HDR template DNA construct comprising the amino acid marker corresponding to the second isoform of the surface protein and subsequently determining the expression of the first or second isoform of said surface protein on said cell, wherein expression of the second isoform indicates a successful HDR event. The invention also relates to a method for editing a genomic location of interest within a eukaryotic cell, and to a method of selectively depleting or enriching an edited cell in a composition of non-edited and edited cells.

Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.

Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.

Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.

Abstract: Device and method for comminution or inactivation of circulating tumor cells (CTC) or tumor cell clusters (CTCC) from a tumor-affected organ or organ part, wherein it is proposed that in the venous drain of the tumor-affected organ or organ part a pump (2) with a pressure-increasing section and a pressure-reducing throttle (13) is arranged and is operated at the output side in its design point given by volumetric flow (Q) and pumping pressure (p) according to the volumetric flow and the blood pressure of the venous drain of the tumor-affected organ or organ part. Circulating tumor cells (CTC) and tumor cell clusters (CTCC) are thus comminuted and inactivated to thus reduce the risk of metastasis formation in cancerous diseases.

Abstract: For exploiting novel use-cases, in particular sophisticated human-machine interaction, with an intraoral electronic tongue monitoring system designed to be worn by a user on the upper or lower jaw and featuring a support sheet bearing a number of intraoral sensors arranged in an array for recording tongue movement and/or tongue pressure, it is proposed that the system comprises at least one extraoral sensor located outside of the oral cavity delimited by the teeth when the system is in place, in particular such that extraoral and/or intraoral and/or interlabial movements of the tongue and/or lip pressure can be recorded with the system and/or such that the system may be used as an input device controlled through tongue movement using a human-machine-interface provided by the system.

Abstract: The present application relates to Pichinde viruses with rearrangements of their open reading frames (“ORF”) in their genomes. In particular. described herein is a modified Pichinde virus genomic segment, wherein the Pichinde virus genomic segment is engineered to carry a viral ORF in a position other than the wild-type position of the ORF. Also described herein are trisegmented Pichinde virus particles comprising one L segment and two S segments or two L segments and one S segment. The Pichinde virus, described herein may be suitable for vaccines md/or treatment of diseases and/or for the use in immunotherapies.

Abstract: Quantitative susceptibility mapping methods, systems and computer-accessible medium include generating images of tissue magnetism property from complex magnetic resonance imaging data using the Bayesian inference approach. The tissue magnetism images is then used to monitor remyelination, such as remyelination in multiple sclerosis patients in response to therapy. Multiple sclerosis lesions defined on magnetic resonance imaging are further characterized on tissue magnetism images into hyperintense, isointense and hypointense parts for measuring remyelination. Thus, magnetic susceptibility information and other tissue properties associated with at least one structure are determined.

Abstract: The invention relates to a preparation system and method for preparing a sample for electron microscopy, the preparation system comprising: a liquid handling system (0) comprising a dispensing head (1), wherein said liquid handling system (0) is configured to aspirate and dispense a volume of a sample via the dispensing head (1), a support structure (2) that is configured to accommodate the sample, a temperature-controlled stage (4) that is configured to keep said support structure (2) at a pre-defined temperature, a first adapter (3) configured to hold said support structure (2), and a transfer mechanism (60) that is configured to be connected to the first adapter (3) holding the support structure (2) and to move said support structure (2) into a container (8) containing a liquid cryogen (80) so that the sample on the support structure (2) contacts the cryogen (80).

Abstract: The present invention relates to the use of a combination of plant extracts from the genera Salvia, Artemisia, Echinacea, and optionally further plant extracts, for the cosmetic treatment of the skin. The invention further relates to cosmetic preparations which comprise such combination of plant extracts. These plant extracts and cosmetic preparations are particularly useful for stimulation of the lymphatic system, including rejuvenation, anti-ageing, detoxification and increased firmness of the skin, for puffy-eye treatment and/or for anti-swelling effects.

Abstract: The invention relates to a method and a computer program for estimating a bilirubin level of a neonate, comprising the steps of: Acquiring a series of bilirubin levels estimated at different time points from a sample obtained from a neonate, Acquiring a plurality of covariates from the neonate, each comprising an information about a neonatal property, Providing a pre-defined bilirubin model function, wherein the bilirubin model function is configured to describe a time course of a bilirubin level of a neonate, —Determining a plurality of model parameters of the bilirubin model function, wherein each model parameter is estimated from at least one covariate of the plurality of covariates and an associated population model parameter, Determining from the series of acquired bilirubin levels and the bilirubin model function with the determined model parameters an expected bilirubin level of the neonate for a time particularly later than a lastly acquired bilirubin level of the series of bilirubin levels.

Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.

Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.